New scan aims to predict drug effectiveness for rare lung disease
NCT ID NCT05467397
Summary
This study is testing whether a special type of PET scan can act as an early sign that the drug rapamycin is working for patients with Lymphangioleiomyomatosis (LAM), a rare lung disease. Seven adult patients with LAM and a specific kidney tumor will receive one or two of these scans over several months. The goal is to see if changes on the scan can predict treatment success faster than current methods.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBEROUS SCLEROSIS COMPLEX are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.